Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine

Journal of General Virology

Volumn 91, Issue 8, 2010, Pages 1898-1908

  Theys, K ^a   Deforche, K ^b   Libin, P ^b   Camacho, R J ^c   Van Laethem, K ^a   Vandamme, A M ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b MyBioData ^*  (Belgium)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; BAYESIAN LEARNING; GENE MUTATION; GENE SEQUENCE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR MODEL; PRIORITY JOURNAL; DRUG COMBINATION; DRUG EFFECT; GENETIC SELECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR EVOLUTION; POINT MUTATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MUTATION, MISSENSE; POINT MUTATION; RNA, VIRAL; SELECTION, GENETIC; ZIDOVUDINE;

EID: 77955298676     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.022657-0     Document Type: Article

References (36)

1. Beerenwinkel, N., Sing, T., Lengauer, T., Rahnenführer, J., Roomp, K., Savenkov, I., Fischer, R., Hoffmann, D., Selbig, J. & other authors (2005a). Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21, 3943-3950. (Pubitemid 41631832)
2. Beerenwinkel, N., Däumer, M., Sing, T., Rahnenführer, J., Lengauer, T., Selbig, J., Hoffmann, D. & Kaiser, R. (2005b). Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 191, 1953-1960. (Pubitemid 40705404)
3. Beerenwinkel, N., Rahnenführer, J., Däumer, M., Hoffmann, D., Kaiser, R., Selbig, J. & Lengauer, T. (2005c). Learning multiple evolutionary pathways from cross-sectional data. J Comput Biol 12, 584-598. (Pubitemid 41170470)
4. Bennett, D. E., Camacho, R. J., Otelea, D., Kuritzkes, D. R., Fleury, F., Kiuchi, M., Heneine, W., Kantor, R., Jordan, M. R. & other authors (2009). Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4, e4724.
5. Boucher, C. A., O'Sullivan, E., Mulder, J. W., Ramautarsing, C., Kellam, P., Darby, G., Lange, J. M., Goudsmit, J. & Larder, B. A. (1992). Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 165, 105-110.
6. Boucher, C. A., Cammack, N., Schipper, P., Schuurman, R., Rouse, P., Wainberg, M. A. & Cameron, J. M. (1993). High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37, 2231-2234. (Pubitemid 23298217)
7. Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M. M., Forbici, F., Bertoli, A., Alcaro, S., Palamara, G. & other authors (2007). Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 81, 11507-11519.
8. Cozzi-Lepri, A., Ruiz, L., Loveday, C., Phillips, A. N., Clotet, B., Reiss, P., Ledergerber, B., Holkmann, C., Staszewski, S. & other authors (2005). Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 10, 791-802. (Pubitemid 41652973)
9. Deforche, K., Silander, T., Camacho, R. J., Grossman, Z., Soares, M. A., Van Laethem, K., Kantor, R., Moreau, Y., Vandamme, A.-M. & other authors (2006). Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. Bioinformatics 22, 2975-2979. (Pubitemid 44884070)
10. Deforche, K., Camacho, R. J., Grossman, Z., Silander, T., Soares, M. A., Moreau, Y., Shafer, R. W., Van Laethem, K., Carvalho, A. P. & other authors (2007a). Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. Infect Genet Evol 7, 382-390. (Pubitemid 46667768)
11. Deforche, K., Camacho, R. J., Van Laethem, K., Shapiro, B., Moreau, Y., Rambaut, A., Vandamme, A.-M. & Lemey, P. (2007b). Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. J Comput Biol 14, 1105-1114. (Pubitemid 350073531)
12. Deforche, K., Camacho, R. J., Grossman, Z., Soares, M. A., Van Laethem, K., Katzenstein, D. A., Harrigan, P. R., Kantor, R., Shafer, R.W. & other authors (2008a). Bayesian network analyses of resistance pathways against efavirenz and nevirapine. AIDS 22, 2107-2115.
13. Deforche, K., Camacho, R. J., Van Laethem, K., Lemey, P., Rambaut, A., Moreau, Y. & Vandamme, A.M. (2008b). Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics 24, 34-41.
14. Deforche, K., Cozzi-Lepri, A., Theys, K., Clotet, B., Camacho, R. J., Kjaer, J., Van Laethem, K., Phillips, A. N., Moreau, Y. & other authors (2008c). Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther 13, 399-407. (Pubitemid 352016733)
15. de Oliveira, T., Deforche, K., Cassol, S., Salminen, M., Paraskevis, D., Seebregts, C., Snoeck, J., van Rensburg, E. J., Wensing, A. M. J. & other authors (2005). An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21, 3797-3800. (Pubitemid 41535530)
16. Gonzales, M. J., Wu, T. D., Taylor, J., Belitskaya, I., Kantor, R., Israelski, D., Chou, S., Zolopa, A. R., Fessel, W. J. & Shafer, R. W. (2003). Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 17, 791-799. (Pubitemid 36547650)
17. Gotte, M. (2007). Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing. PLoS Med 4, e346.
18. Holford, N. H. & Sheiner, L. B. (1982). Kinetics of pharmacologic response. Pharmacol Ther 16, 143-166.
19. Johnson, V. A., Brun-Vezinet, F., Clotet, B., Gunthard, H. F., Kuritzkes, D. R., Pillay, D., Schapiro, J. M. & Richman, D. D. (2008). Update of the drug resistance mutations in HIV-1. Top HIV Med 16, 138-145.
20. Kantor, R., Machekano, R., Gonzales, M. J., Dupnik, K., Schapiro, J. M. & Shafer, R. W. (2001). Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language and sequence analysis programs. Nucleic Acids Res 29, 296-299. (Pubitemid 32054474)
21. Miller, V., Phillips, A., Rottmann, C., Staszewski, S., Pauwels, R., Hertogs, K., de Bthune, M. P., Kemp, S. D. & other authors (1998). Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 177, 1521-1532.
22. Myllymäki, P., Silander, T., Tirri, H. & Uronen, P. (2002). B-Course: a web-based tutorial for Bayesian and causal data analysis. Int J Artif Intell Tools 11, 396-387.
23. Pearl, J. (1988). Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference. San Mateo, CA: Morgan Kaufmann.
24. Rhee, S. Y., Fessel, J. W., Zolopa, A. R., Hurley, L., Liu, T., Taylor, J., Nguyen, D. P., Slome, S., Klein, D. & other authors (2005). HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 192, 456-465.
25. Rhee, S. Y., Liu, T. F., Holmes, S. P. & Shafer, R. W. (2007). HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol 3, e87.
26. Saracino, A., Monno, L., Scudeller, L., Cibelli, D. C., Tartaglia, A., Punzi, G., Torti, C., Lo Caputo, S, Mazzotta, F. & other authors (2006). Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. J Med Virol 78, 9-17.
27. Shafer, R. W., Iversen, A. K., Winters, M. A., Aguiniga, E., Katzenstein, D. A. & Merigan, T. C. (1995). Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis 172, 70-78.
28. Shahriar, R., Rhee, S. Y., Liu, T. F., Fessel, W. J., Scarsella, A., Towner, W., Holmes, S. P., Zolopa, A. R. & Shafer, R. W. (2009). Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother 53, 4869-4878.
29. Sturmer, M., Staszewski, S., Doerr, H. W., Larder, B., Bloor, S. & Hertogs, K. (2003). Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214. Antimicrob Agents Chemother 47, 54-61. (Pubitemid 36070342)
30. Svicher, V., Sing, T., Santoro, M. M., Forbici, F., Rodríguez- Barrios, F., Bertoli, A., Beerenwinkel, N., Bellocchi, M. C., Gago, F. & other authors (2006). Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 80, 7186-7198.
31. Swofford, D. L. (2000). PAUP*: phylogenetic analysis using parsimony (*and other methods), version 4. Sunderland, MA: Sinauer Associates.
32. Van Laethem, K. & Vandamme, A.-M. (2006). Interpreting resistance data for HIV-1 therapy management - know the limitations. AIDS Rev 8, 37-43. (Pubitemid 43757078)
33. Van Vaerenbergh, K., Van Laethem, K., Albert, J., Boucher, C. A., Clotet, B., Floridia, M., Gerstoft, J., Hejdeman, B., Nielsen, C. & other authors (2000). Prevalence and characteristics of multinucleosideresistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 44, 2109-2117. (Pubitemid 30484434)
34. Vingerhoets, J., Azijn, H., Fransen, E., De Baere, I., Smeulders, L., Jochmans, D., Andries, K., Pauwels, R. & de Bethune, M. P. (2005). TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 79, 12773-12782. (Pubitemid 41433197)
35. Wainberg, M. A., Brenner, B. G. & Turner, D. (2005). Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 49, 1671-1678.
36. Zaccarelli, M., Perno, C. F., Forbici, F., Soldani, F., Bonfigli, S., Gori, C., Trotta, M. P., Bellocchi, M. C., Liuzzi, G. & other authors (2004). Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis 38, 433-437. (Pubitemid 38200125)